Published in J Immunol on May 01, 1999
Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother (2009) 2.35
Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest (2002) 2.21
CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin Cancer Res (2013) 1.90
In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res (2011) 1.62
4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. J Immunol (2007) 1.57
Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J Clin Invest (2010) 1.53
Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice. J Immunol (2007) 1.52
CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice. J Clin Invest (2003) 1.52
Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy. J Exp Med (1999) 1.37
CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci U S A (2002) 1.34
Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses. Proc Natl Acad Sci U S A (2004) 1.27
Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD). Philos Trans R Soc Lond B Biol Sci (2005) 1.26
Immune suppression or enhancement by CD137 T cell costimulation during acute viral infection is time dependent. J Clin Invest (2007) 1.17
The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov (2015) 1.09
A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity. Vaccine (2009) 1.09
Deficiency for costimulatory receptor 4-1BB protects against obesity-induced inflammation and metabolic disorders. Diabetes (2011) 1.09
Engagement of the CD137 (4-1BB) costimulatory molecule inhibits and reverses the autoimmune process in collagen-induced arthritis and establishes lasting disease resistance. Immunology (2004) 1.08
c-Jun NH(2)-terminal kinase (JNK)1 and JNK2 signaling pathways have divergent roles in CD8(+) T cell-mediated antiviral immunity. J Exp Med (2002) 1.07
CD137 costimulation of CD8+ T cells confers resistance to suppression by virus-induced regulatory T cells. J Immunol (2008) 1.05
Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy. ISRN Oncol (2013) 1.04
The dual functions of fas ligand in the regulation of peripheral CD8+ and CD4+ T cells. Proc Natl Acad Sci U S A (2000) 1.03
Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice. PLoS One (2010) 1.02
CD8+ T cell dysfunction and increase in murine gammaherpesvirus latent viral burden in the absence of 4-1BB ligand. J Immunol (2007) 1.01
CD137-CD137 Ligand Interactions in Inflammation. Immune Netw (2009) 0.99
Opposing effects of CD70 costimulation during acute and chronic lymphocytic choriomeningitis virus infection of mice. J Virol (2011) 0.99
Effector CD8 T cells possess suppressor function after 4-1BB and Toll-like receptor triggering. Proc Natl Acad Sci U S A (2003) 0.98
Regulating functional cell fates in CD8 T cells. Immunol Res (2010) 0.95
Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice. J Transl Med (2010) 0.94
Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patients. Oncoimmunology (2012) 0.92
The tumour necrosis factor/TNF receptor superfamily: therapeutic targets in autoimmune diseases. Clin Exp Immunol (2011) 0.92
Immunotherapy for liver tumors: present status and future prospects. J Biomed Sci (2009) 0.92
Radiotherapy enhances antitumor effect of anti-CD137 therapy in a mouse Glioma model. Radiat Res (2010) 0.91
4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine. Immunology (2004) 0.91
4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy. BMB Rep (2014) 0.90
Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors. Immunotherapy (2011) 0.89
Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137. Clin Pharmacol (2013) 0.89
A cell-intrinsic requirement for NF-κB-inducing kinase in CD4 and CD8 T cell memory. J Immunol (2013) 0.89
On CD28/CD40 ligand costimulation, common gamma-chain signals, and the alloimmune response. J Immunol (2002) 0.86
Adjuvant effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer. Int J Biol Sci (2007) 0.85
Induction of 4-1BB (CD137) expression by DNA damaging agents in human T lymphocytes. Immunology (2002) 0.85
Regulation of mouse 4-1BB expression: multiple promoter usages and a splice variant. Mol Cells (2011) 0.85
CD134/CD137 dual costimulation-elicited IFN-γ maximizes effector T-cell function but limits Treg expansion. Immunol Cell Biol (2013) 0.84
Origins and functional basis of regulatory CD11c+CD8+ T cells. Eur J Immunol (2009) 0.84
Anti-leukemia activity of MS-275 histone deacetylase inhibitor implicates 4-1BBL/4-1BB immunomodulatory functions. PLoS One (2009) 0.83
Induction of a VLA-2 (CD49b)-expressing effector T cell population by a cell-based neuroblastoma vaccine expressing CD137L. J Immunol (2008) 0.83
T cell vaccinology: exploring the known unknowns. Vaccine (2012) 0.83
4-1BB Signaling Enhances Primary and Secondary Population Expansion of CD8+ T Cells by Maximizing Autocrine IL-2/IL-2 Receptor Signaling. PLoS One (2015) 0.82
Blockade of 4-1BB and 4-1BBL interaction reduces obesity-induced skeletal muscle inflammation. Mediators Inflamm (2013) 0.82
Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation. Oncoimmunology (2013) 0.82
Transgenic 4-1BBL-engineered vaccine stimulates potent Gag-specific therapeutic and long-term immunity via increased priming of CD44(+)CD62L(high) IL-7R(+) CTLs with up- and downregulation of anti- and pro-apoptosis genes. Cell Mol Immunol (2014) 0.82
Integrating costimulatory agonists to optimize immune-based cancer therapies. Immunotherapy (2009) 0.81
Augmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancement. J Immunother (2011) 0.81
CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses. Oncoimmunology (2015) 0.81
Immunotherapy for malignant glioma. Surg Neurol Int (2015) 0.81
Potent induction of B- and T-cell immunity against human carcinoembryonic antigen-expressing tumors in human carcinoembryonic antigen transgenic mice mediated by direct lentivector injection. Mol Cancer Ther (2009) 0.80
Immune modulation through 4-1BB enhances SIV vaccine protection in non-human primates against SIVmac251 challenge. PLoS One (2011) 0.80
Targeting 4-1BB (CD137) to enhance CD8 T cell responses with poxviruses and viral antigens. Front Immunol (2012) 0.79
4-1BB ligand activates bystander dendritic cells to enhance immunization in trans. J Immunol (2014) 0.78
Expression of 4-1BB and 4-1BBL in thymocytes during thymus regeneration. Exp Mol Med (2009) 0.78
Retroviral immunology: lessons from a mouse model. Immunol Res (2009) 0.78
Triple expression of B7-1, B7-2 and 4-1BBL enhanced antitumor immune response against mouse H22 hepatocellular carcinoma. J Cancer Res Clin Oncol (2010) 0.77
In vivo accumulation of T cells in response to IL-2/anti-IL-2 mAb complexes is dependent in part on the TNF family ligand 4-1BBL. Immunol Cell Biol (2011) 0.77
Absence of 4-1BB reduces obesity-induced atrophic response in skeletal muscle. J Inflamm (Lond) (2017) 0.75
c-IAP ubiquitin protein ligase activity is required for 4-1BB signaling and CD8(+) memory T-cell survival. Eur J Immunol (2015) 0.75
CD137: costimulator turns suppressor? Immunology (2004) 0.75
Intrinsic 4-1BB signals are indispensable for the establishment of an influenza-specific tissue-resident memory CD8 T-cell population in the lung. Mucosal Immunol (2017) 0.75
Development of CAR T cells designed to improve antitumor efficacy and safety. Pharmacol Ther (2017) 0.75
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med (1997) 3.89
4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med (1997) 3.31
Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity (1996) 2.74
Patterns of antigenic expression on human monocytes as defined by monoclonal antibodies. Cell Immunol (1983) 2.59
NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol (1998) 2.11
Monoclonal antibodies against Neisseria gonorrhoeae: production of antibodies directed against a strain-specific cell surface antigen. Infect Immun (1981) 2.09
IL-6 rescues resting mouse T cells from apoptosis. J Immunol (1997) 1.89
Development of eosinophilic airway inflammation and airway hyperresponsiveness requires interleukin-5 but not immunoglobulin E or B lymphocytes. Am J Respir Cell Mol Biol (1999) 1.64
Induction and immunological properties of tumor necrosis factor. J Reticuloendothel Soc (1978) 1.53
Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. J Immunol (2000) 1.45
Generation and characterization of monoclonal antibodies reactive with human B lymphocytes. J Immunol (1983) 1.45
OX-40: life beyond the effector T cell stage. Semin Immunol (1998) 1.43
Macrophage factor controlling differentiation of B cells. J Immunol (1979) 1.28
Allergic airway sensitization induces T cell activation but not airway hyperresponsiveness in B cell-deficient mice. Proc Natl Acad Sci U S A (1997) 1.25
4-1BB costimulation is required for protective anti-viral immunity after peptide vaccination. J Immunol (2000) 1.21
Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. Eur J Immunol (1998) 1.18
Antibodies to the common leukocyte antigen (T200) inhibit an early phase in the activation of resting human B cells. J Immunol (1987) 1.18
p56lck association with CD4 is required for the interaction between CD4 and the TCR/CD3 complex and for optimal antigen stimulation. J Immunol (1992) 1.15
CD40 activation boosts T cell immunity in vivo by enhancing T cell clonal expansion and delaying peripheral T cell deletion. J Immunol (1999) 1.11
Stimulation of tyrosine phosphorylation and calcium mobilization by Fc gamma receptor cross-linking. Regulation by the phosphotyrosine phosphatase CD45. J Immunol (1993) 1.10
CD45-protein tyrosine phosphatase cross-linking inhibits T cell receptor CD3-mediated activation in human T cells. J Immunol (1989) 1.08
ZAP-70 tyrosine kinase, CD45, and T cell receptor involvement in UV- and H2O2-induced T cell signal transduction. J Biol Chem (1994) 1.06
Distribution of antigens defined by OKB monoclonal antibodies on benign and malignant lymphoid cells and on nonlymphoid tissues. Blood (1984) 1.05
Early preferential stimulation of gamma delta T cells by TNF-alpha. J Immunol (1998) 1.05
Cell membrane perturbation of resting T cells and thymocytes causes display of activation antigens. J Exp Med (1983) 1.03
Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival. Transpl Int (2004) 1.02
Ubiquitin carrier protein-catalyzed ubiquitin transfer to histones. Mechanism and specificity. J Biol Chem (1988) 1.02
Levels of active ubiquitin carrier proteins decline during erythroid maturation. J Biol Chem (1988) 1.01
The two membrane proximal domains of CD4 interact with the T cell receptor. J Exp Med (1996) 0.99
Rapid and reliable cloning of antibody variable regions and generation of recombinant single chain antibody fragments. Tissue Antigens (1996) 0.94
Immunogenic Ia-binding peptides immobilize the Ia molecule and facilitate its aggregation on the B cell membrane. Control by the M1s-1 gene. J Immunol (1990) 0.92
Ascorbic acid is a potent inhibitor of various forms of T cell apoptosis. Cell Immunol (1999) 0.89
Characterization of a CD43/leukosialin-mediated pathway for inducing apoptosis in human T-lymphoblastoid cells. J Biol Chem (1996) 0.88
Polyspecific self-reactive antibodies in individuals infected with human immunodeficiency virus facilitate T cell deletion and inhibit costimulatory accessory cell function. J Infect Dis (1999) 0.88
Feeding by the tick, Ixodes scapularis, causes CD4(+) T cells responding to cognate antigen to develop the capacity to express IL-4. Parasite Immunol (2007) 0.88
Analysis of 4-1BBL and laminin binding to murine 4-1BB, a member of the tumor necrosis factor receptor superfamily, and comparison with human 4-1BB. J Biol Chem (1997) 0.88
OX40 ligation enhances cell cycle turnover of Ag-activated CD4 T cells in vivo. Cell Immunol (2001) 0.86
Differential clonal expansion of CD4 and CD8 T cells in response to 4-1BB ligation: contribution of 4-1BB during inflammatory responses. Immunol Lett (2001) 0.85
Deletion of active human suppressor T lymphocytes from peripheral blood by Sephadex G-10 filtration. J Immunol Methods (1982) 0.85
Agonistic activity of a CD40-specific single-chain Fv constructed from the variable regions of mAb G28-5. Crit Rev Immunol (1997) 0.84
Analysis of expression and function of the costimulatory molecule 4-1BB in alloimmune responses. Transplantation (2000) 0.83
CD137 ligand prevents the development of T-helper type 2 cell-mediated allergic asthma by interferon-gamma-producing CD8+ T cells. Clin Exp Allergy (2007) 0.83
The application of monoclonal antibodies to the characterization and diagnosis of lymphoid neoplasms: a review of recent studies. Diagn Immunol (1983) 0.83
Suppression of T-cell-dependent immune responses in monkeys by CTLA4Ig. Transplant Proc (1996) 0.80
Rapid αβ T-cell responses orchestrate innate immunity in response to Staphylococcal enterotoxin A. Mucosal Immunol (2013) 0.80
Classification of human lymphocytes and monocytes with the OK series of monoclonal antibodies. Diagn Immunol (1983) 0.80
Costimulation by CD28 sFv expressed on the tumor cell surface or as a soluble bispecific molecule targeted to the L6 carcinoma antigen. Tissue Antigens (1996) 0.79
In vivo effects of prostaglandin E2 and arachidonic acid on phagocytosis of fluorescent methacrylate microbeads by rat peritoneal macrophages. J Histochem Cytochem (1982) 0.78
CTL hyporesponsiveness induced by 2,3,7, 8-tetrachlorodibenzo-p-dioxin: role of cytokines and apoptosis. Toxicol Appl Pharmacol (2000) 0.77
Increased CD4+ T cell-dependent anti-erythrocyte antibody levels following the onset of parasite egg production in Schistosoma mansoni infected mice. Parasite Immunol (1994) 0.77
Resting and activation antigens of T cells: studies with OKT10 and OKT20 monoclonal antibodies. Diagn Immunol (1983) 0.76
MHC class I molecules on CD4 T cells regulate receptor-mediated activation signals. Cell Immunol (1999) 0.75
Evidence for polyclonal B cell activation as the mechanism for LCMV-induced autoimmune hemolytic anemia. Immunol Lett (1992) 0.75
Surface expression of CD28 single chain Fv for costimulation by tumor cells. Immunol Rev (1996) 0.75